After downsizing its sought-after haul, GlycoMimetics is postponing its $64 million IPO plans, a sign that the year's investor frenzy over biotech debuts may not be welcoming all comers. Early last month, the Gaithersburg, MD-based company filed to rake in up to $86 million in a first-time offering, scaling it back to $64 million on Oct. 28. Article